Peter Dall
Lueneburg, NI, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer-2026 Update.
Journal: Breast (Edinburgh, Scotland)
Published: April 29, 2026
AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: March 24, 2026
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.
Journal: Breast care (Basel, Switzerland)
Published: March 08, 2026
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.
Journal: Breast care (Basel, Switzerland)
Published: March 05, 2026
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: September 09, 2025
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.
Journal: Breast care (Basel, Switzerland)
Published: February 26, 2025
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.
Journal: Breast care (Basel, Switzerland)
Published: February 18, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.
Journal: Breast (Edinburgh, Scotland)
Published: December 23, 2024
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
Journal: International journal of cancer
Published: September 20, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 08, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Journal: Geburtshilfe und Frauenheilkunde
Published: May 01, 2024
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
Journal: Breast care (Basel, Switzerland)
Published: March 25, 2024
Last Updated: 09/26/2026